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Summary
Despite the increasing use of dendritic cell (DC) vaccination in clinical trials,
optimal conditions for the generation of functionally mature DCs remain to
be established. The current standard DC maturation protocol for clinical
trials has been used as an inflammatory cytokine cocktail [tumour necrosis
factor (TNF)-a, interleukin (IL)-1b, IL-6 and prostaglandin E2], but this cock-
tail induced insufficient maturation of DCs derived from elutriated mono-
cytes when cultured in X-VIVO 15. The aim of this study was to define
effective combinations of stimulators for generating functionally mature DCs
from elutriated monocytes under current good manufacturing practice
conditions. We compared the functional capacity of DCs in response to all
possible pairwise combinations of four different classes of stimuli: TNF-a,
peptidoglycan, polyinosinic : polycytidylic acid [poly(I:C)] and soluble CD40
ligand (CD40L). Maturation status of DCs stimulated with combination of
four stimuli was similar to that of the cytokine cocktail as assessed by the cell
surface phenotype. However, only the combination of poly(I:C) + CD40L
induced complete functional activation of the whole DC population, assessing
IL-12p70 production, allostimulatory activity, migratory response to CCL19
and T helper 1-polarizing capacity. Thus, the protocol based on the combina-
tion of poly(I:C) and CD40L is more effective for the induction of clinical-
grade DCs from elutriated monocytes than the standard cytokine cocktail.
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Introduction
Dendritic cells (DCs) play a pivotal role in cellular immunity
by processing antigens in peripheral tissues and presenting
them to T cells in secondary lymphoid tissues, thereby
initiating primary immune responses [1,2]. These unique
characteristics make DCs potentially suitable for immuno-
therapy against malignant and infectious diseases [3,4].
Since the first published clinical trial of DC vaccination
in 1995, numerous studies have been performed and have
demonstrated the safety of such strategies, but in most cases
the clinical outcomes did not meet expectations because of
suboptimal dosages, immunological potency of the injected
DC and host immunodeficiency imposed by the tumours.
To overcome these obstacles, new approaches to improve
DC-mediated immunotherapeutic strategies are under
investigation, including the use of different vaccine cell
formats, cell numbers, vaccination schedules, sites of vacci-
nation and maturation stages of DCs [5,6].
As the number of clinical studies using monocyte-derived
DCs for cancer immunotherapy continues to increase, it is
essential to provide advanced protocols for generating suffi-
cient quantities of well-characterized, highly immunogenic
DCs according to current good manufacturing practice
(cGMP) guidelines. The elutriation method for monocyte
enrichment is based on the physical separation of cells by
counterflow centrifugation, in which cells are separated by
size and density [7]. Elutriation with the Elutra™ cell sepa-
ration system (Gambro BCT, Lakewood, CO, USA) gives a
high recovery of monocytes directly from leukapheresis
products that can be differentiated further into DCs suitable
for vaccination protocols [8]. Because the whole process of
elutriation can be conducted in a closed system, clinical-
grade DCs can be obtained easily. DCs generated from
elutriated monocytes show the same characteristics as DCs
made from monocytes purified by plastic adherence [7–9].
Several known molecules or molecular cocktails have
been reported to trigger DC maturation, including: (i)
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proinflammatory cytokines such as tumour necrosis factor
(TNF)-a, interleukin (IL)-1b and IL-6 [10]; (ii) molecules
derived from pathogenic agents, such as lipopolysaccharide,
lipoteichoic acid, cytidine–phosphate–guanosine oligo-
nucleotides [10–12], double-stranded RNA or polyino-
sinic : polycytidylic acid [poly(I:C)] [13]; and (iii) T
cell-dependent signal such as CD40 ligand (CD40L) and
interferon (IFN)-g [14]. The effect of combinations of
the aforementioned maturation factors on the maturation
of elutriated monocyte-derived DCs remains relatively
unexplored. Currently, most clinical trials utilize a cytokine
cocktail that includes IL-1b, IL-6, TNF-a and prostaglandin
E2 (PGE2) [15]. However, mature DCs (mDCs) with cytokine
cocktail failed to produce IL-12p70. Therefore, we sought to
determine whether combinations of various maturation
factors may co-operate in DC maturation from elutriated
monocytes and thus provoke the potent T helper 1 (Th1)-
biased DC activity for clinical application. To this end, we
selected maturation factors from three broad classes of
stimuli: microbes and their products recognized by Toll-like
receptors (TLRs) [peptidoglycan (PGN) and poly(I:C)],
a proinflammatory mediator (TNF-a) and an activated
T cell-derived factor (CD40L).
Materials and methods
Leukapheresis and elutriation
A total of seven leukapheresis products were obtained from
seven healthy donors after obtaining written informed
consent using the COBE Spectra Apheresis System (Gambro
BCT), as described previously [16]. The study protocols were
approved by the local ethics committee and met the guide-
lines for blood donation. Continuous counterflow elutria-
tion was performed with the Elutra™ cell separator (Gambro
BCT), and with Hanks’s buffered salt solution (HBSS; Bio-
Whittaker, Walkersville, MD, USA) used as elutriation buffer
in automation mode. The leukapheresis product was loaded
via the inlet pump into the constantly rotating (2400 rpm)
elutriation chamber. In automation mode, the cell separator
produced five elutriation fractions, each specified by a cen-
trifuge speed, loading or elutriation buffer flow rate and
process volume. The final monocyte-rich fraction was col-
lected from the chamber into the final collection bag after the
complete stop of the centrifuge. All procedures were con-
ducted according to the manufacturer’s recommendations.
The DC generation
After removing the HBSS elutriation buffer, elutriated
monocytes were plated on T75 culture flasks (Greiner
Bio-One GmbH, Frickenhausen, Germany) in complete
medium, i.e. X-VIVO 15 (Bio-Whittaker), 100 U/ml penicil-
lin, 100 mg/ml streptomycin and 2 mM l-glutamine,
2% human AB plasma. Adherent cells were cultured in
250 ng/ml granulocyte–macrophage colony-stimulating
factor (GM-CSF) (kindly provided by LG Life Sciences,
Daejon, Korea) and 1000 U/ml recombinant human IL-4
(BD Biosciences, San Jose, CA, USA) for 6 days. Cultures
were fed every other day by removing half the supernatant
and adding fresh medium with a full dose of cytokines. On
day 6, immature (iDCs) were harvested and replated at
1 ¥ 106/ml on 24-well plates (Geiner). To induce maturation,
iDCs were stimulated with one or a combination of the
following reagents for 48 h: TNF-a (10 ng/ml; BD Bio-
sciences), poly(I:C) (20 mg/ml; Sigma Chemical Co., St
Louis, MO, USA), Staphylococcus aureus PGN (10 mg/ml;
Fluka, Milwaukee, WI, USA), soluble human recombinant
CD40L (1 mg/ml; Chemicon, Temecula, CA, USA), cytokine
cocktail consisting of 10 ng/ml IL-1b, 10 ng/ml IL-6,
10 ng/ml TNF-a (all from BD Biosciences) and 10-7 M PGE2
(Sigma). After 48 h, the cells were harvested and analysed.
Flow cytometry analysis
To examine cell surface markers, samples for immunophe-
notyping were taken at the start of the culture and after DC
maturation (day 8). The following commercial monoclonal
antibodies (mAb) were used: anti-CD11c, -CD14, -CD1a,
-CD83, -CD86, -human leucocyte antigen D-related (HLA-
DR), CCR7, CD40 and CD80 (all from BD Biosciences).
Contamination with natural killer cells, T cells and B cells
was detected using CD16, CD56, CD3 and CD19 mAb (all
from BD Biosciences). Cells were collected and analysed
using the Cytomics™ Flow Cytometer (Beckman Coulter,
Fullerton, CA, USA). Non-relevant antibodies of the recom-
mended isotypes were included as controls. Data analysis
was performed by WinMDI (Scripps Institute, La Jolla, CA,
USA) or cxp and fcs 3·0 software for FC500 (Beckman
Coulter). Cells were gated electronically according to light-
scatter properties to exclude cell debris or dead cells stained
with propidium iodide (Sigma). Results were expressed as
median fluorescence intensity.
Allogeneic mixed leucocyte reaction assay
The DCs were harvested, washed and resuspended in RPMI-
1640 + 10% fetal bovine serum (FBS). A total of 2 ¥ 105 allo-
geneic T cells were incubated with irradiated DCs (30 Gy)
at different responder : stimulator ratios ranging between
10:1 and 1280:1 in 96-well flat-bottomed plates. After 4 days
of co-culture, the cells were pulsed with [3H]-thymidine
(0·5 mCi/ml final concentration) and incorporation was
measured after 16 h. Responses were reported as mean of
triplicate counts per minute standard error of the mean
(s.e.m.) minus the background counts.
Enzyme-linked immunosorbent assay
The culture supernatants were collected and frozen at -20°C
for cytokine quantification. Production of IL-12p70 and
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IL-10 in cell culture supernatants was measured by enzyme-
linked immunosorbent assay (ELISA) using the OptEIA
ELISA kit (BD Biosciences).
Flow cytometric detection of IFN-g and IL-4 in
DC-activated T cells
Intracellular cytokine expression was assessed in T cells using
previously described methods, with minor modifications
[17]. DCs, immature or mature, were co-cultured with allo-
geneic T cells for 7 days at a 1:10 ratio. Maturation stimuli
were poly(I:C) (20 mg/ml) alone or a combination of
poly(I:C) (20 mg/ml) with TNF-a (10 ng/ml), PGN (10 mg/
ml) and CD40L (1 mg/ml). Controls were made without
addition of DCs. CD4+ T cells were then washed extensively
and restimulated with 20 ng/ml of phorbol 12-myristate
13-acetate and 1 mg/ml of ionomycin (all from Sigma) for
8 h. Brefeldin A (10 mg/ml; Sigma) was added during the last
6 h to accumulate most of the cytokine in the Golgi complex.
Cells were then fixed and permeabilized with the Cytofix/
Cytoperm kit (BD Biosciences) and incubated with
fluorescein isothiocyanate (FITC)-labelled anti-IFN-g and
phycoerythrin-labelled anti-IL-4 mAbs (BD Biosciences).
Cells were collected and analysed as described above.
Migration assay
The DC migration towards CCL19 [major inflammatory
protein (MIP)-3b] or IL-8 (both from Peprotech, Rocky Hill,
NJ, USA) was measured in 24-well Transwell plates with
polycarbonate filters of 5 mm pore size (Corning Costar, New
York, NY, USA); 600 ml of serum-free culture medium
(RPMI-1640) with either 10 ng/ml of CCL19 or 50 ng/ml of
IL-8 was added to the bottom of the chambers. DCs (1 ¥ 105)
were added to the upper chamber in a total volume of 100 ml
medium. After 2 h of incubation, the migrated cells in the
bottom chamber were collected and counted with a flow
cytometer for 1 min at high flow speed.
Statistical analysis
All the experiments in this study were conducted at least
three times. If not indicated otherwise, experimental values
are given as means s.e.m. of triplicate assays. Statistical
comparisons were performed by analysis of variance test
using spss for Windows version 11·0 (SPSS Inc., Chicago, IL,
USA). Any P-value below 0·05 was considered statistically
significant.
Results
Generation of DCs from elutriated monocytes
With a total of seven leukapheresis products, elutriations
were performed independently. In the leukapheresis
products, the total mononuclear cell count was
7·3 0·4 ¥ 109 cells and the mean percentage of CD14+
monocytes was 15·8 4·2%, which increased to
68·9 5·8% after elutriation (data not shown). We found
that the generation of DCs from elutriated monocytes
was inhibited significantly in the absence of FBS or human
AB plasma due to irreversible adherence and macrophage
differentiation. As it is important to obtain a high yield of
mDCs for vaccination purposes, we compared the yields of
DC upon culture with conventional media (RPMI-1640
supplemented with 10% FBS) to X-VIVO 15 in the pres-
ence of various concentration of human AB plasma.
GM-CSF and IL-4 were added to the elutriated monocytes
in the presence of different concentrations of human
AB plasma, and after 6 days of culture iDCs were matured
with the cytokine cocktail (TNF-a, IL-1b, IL-6 and PGE2).
After 48 h, cells were harvested and the yield and pheno-
type of DCs were analysed. DC yield was defined as per-
centage of cultured monocytes (Table 1). As dislodging
DCs cultured with X-VIVO 15 (without plasma) required
more handling than harvesting cells from other conditions,
the yield of DCs was influenced significantly by the pres-
ence of human AB plasma. We found that 2% AB plasma
was optimal for DC yield, which was comparable to that of
DCs cultured with RPMI-1640 + 10% FBS. Furthermore,
the addition of human plasma induced monocytes to
become more mDCs, as evidenced by phenotype analysis
(Fig. 1a).
The DCs generated in the presence of human plasma dis-
played a high expression of HLA-DR, CD86 with moderate
CD40 and CD80 that are comparable to that cultured with
RPMI-1640 and 10% FBS. It is of note that mDCs cultured
with serum-free X-VIVO 15 expressed high levels of CD1a
but little CD83, whereas the addition of plasma increased
the fraction of CD83 expressing DCs. Meanwhile, the addi-
tion of human plasma completely abolished CD1a expres-
sion from DCs cultured with X-VIVO 15. As reported
previously [8], CD14 expression by mature as well as iDCs
was minimal in our setting. Although DCs cultured in
RPMI-1640 + 10% FBS exhibited stronger allostimulatory
capacity than those cultured in X-VIVO 15 + 2% human
AB plasma (Fig. 1b), we selected X-VIVO + 2% human AB
plasma as a GMP-grade medium for considering clinical
applicability. The phagocytic capacity of resultant iDCs
Table 1. Yield of dendritic cells (DCs) as percentage of the cultured
monocytes (n = 3).
Media Yield (% s.d.)
RPMI-1640 + 10% FBS 72·3 10·3
X-VIVO 15 37·7 5·9
X-VIVO 15 + 2% AB plasma 52·3 8·7
X-VIVO 15 + 5% AB plasma 55·9 9·3
X-VIVO 15 + 10% AB plasma 60·7 9·3
FBS, fetal bovine serum; s.d., standard deviation.
Poly(I:C) plus CD40L on functionally matured DC
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measured by the cellular uptake of FITC-labelled dextran
was comparable to that of conventional iDCs generated
from CD14+ purified monocytes cultured in RPMI-1640
(data not shown). As reported previously [18], the contami-
nation of granulocytes (14·0 3·0%) in the elutriated
product had no significant effect on the viability, pheno-
type, cytokine production and stimulatory capacity of the
DCs generated.
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Fig. 1. Phenotype and allostimulatory activity of mature dendritic cells (mDCs) generated from elutriated monocytes. (a) Elutriated
monocyte-derived immature DCs (iDCs) were stimulated with tumour necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6 and prostaglandin E2
(PGE2) for 48 h in the presence of RPMI-1640 + 10% fetal bovine serum (FBS), serum-free X-VIVO 15 and X-VIVO 15 with 2% human AB plasma.
Expression of CD83, CD1a, human leucocyte antigen D-related (HLA-DR), CD86, CD40 and CD80 was analysed by flow cytometry. Compared
with the DCs cultured with RPMI-1640 + 10% FBS, DCs cultured with X-VIVO 15 expressed low level of CD83. The representative result of one1
of four experiments is shown. (b) Allogeneic mixed leucocyte reaction assay. The mDCs were generated in the presence of RPMI-1640 + 10% FBS
or X-VIVO 15 + 2% human AB plasma stimulated with TNF-a, IL-1b, IL-6 and PGE2. Allogeneic peripheral blood mononuclear cells (105
cells/well) as responders were stimulated with graded numbers of mature and immature DCs (ratio ranging between 1:20 and 1:640). Proliferation
was measured by [3H]-thymidine incorporation on day 5. Results from one representative of three independent experiments are shown.
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Phenotypical analysis of DCs matured with
different stimuli
To test the responsiveness of iDCs to single or combinations
of four different maturation stimuli, we evaluated the
expression of CD80, CD86, CD40, CD83, HLA-DR and
CCR7 after 48 h exposure of iDCs to TNF-a, CD40L,
poly(I:C) and PGN. As a control, iDCs were matured with a
cytokine cocktail containing IL-1b, IL-6, TNF-a and PGE2.
DCs matured with all the stimuli displayed typical mDC
morphology and were indistinguishable from DCs matured
with cytokine cocktail. Although the yields and viabilities of
mDCs were not significantly different from one another
(data not shown), phenotypical analysis revealed that DC
maturation was affected differently by the stimuli employed
(Fig. 2). Exposure of DC to single or combinations of the
maturation factors for 48 h induced expression of CD80,
CD86, CD40 and HLA-DR with considerably weaker expres-
sion of CD83 and CCR7. CD83 and CD40 were up-regulated
significantly only by cytokine cocktail expressed. Although
poly(I:C) induced the expression of CD86, HLA-DR and
CCR7 on DCs comparable to that of a cytokine cocktail, little
or no additive effect of the combination of poly(I:C) with
other stimuli was detected. PGN alone or in combination
with CD40L or TNF-a had little impact on marker expres-
sion during DC maturation.
Immunostimulatory capacity of DCs in an allogeneic
mixed lymphocyte reaction
To evaluate the allostimulatory capacities of DCs matured
with different stimuli, we performed an allogeneic mixed
leucocyte reaction assay. DCs matured with different stimuli
induced proliferative responses more effectively than iDCs
(Fig. 3a). Increases in allogeneic T cell proliferation were
apparent in all DC : T cell ratios tested and were consistent
for all donors tested (data not shown). DCs matured with
poly(I:C) + CD40L presented much stronger allostimulatory
activity than DCs matured with cytokine cocktail, as well as
other stimuli. There was no significant difference in allo-
stimulatory capacity between DCs matured with cytokine
cocktail and DCs matured with poly(I:C) alone, TNF-
a + poly(I:C) or PGN + poly(I:C). The other combinations
of stimuli failed to provide either additive or synergistic
effects on T cell proliferation.
Cytokine production by DCs matured with
different stimuli
The level of IL-12 production by DCs is a major factor
driving the development of Th1 cells. IL-10, a pleiotropic
cytokine known to have inhibitory effects on the accessory
functions of DCs, appears to play a central role in preventing
overly pathological Th1 or Th2 responses in a variety of
settings. Thus, we studied the production of IL-10 and
IL-12p70 by DCs differentiated under the influence of the
above factors (Fig. 3b and c). The production of IL-12p70
and IL-10 by either iDC or mDCs cultured with cytokine
cocktail was low or just detectable. Major enhancement of
IL-10 production was caused by PGN. While PGN, CD40L
and TNF-a alone did not induce IL-12p70, only poly(I:C)
induced consistently high levels of IL-12p70 and low levels
of IL-10. Among the combinations, PGN + poly(I:C),
CD40L + poly(I:C) and TNF-a + poly(I:C) were the
strongest stimulators of IL-12p70 secretion. In contrast,
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Fig. 2. Phenotypic profiles of dendritic cells (DCs) stimulated with
different combinations of maturation factors. Immature DCs were
stimulated for 48 h with single or pairwise combinations of tumour
necrosis factor (TNF)-a, CD40L, polyinosinic : polycytidylic acid
[poly(I:C)] and peptidoglycan (PGN), and maturation status was
assessed by expression of cell surface markers (CD83, HLA-DR, CD86,
CD40, CD80 and CCR7). As a positive control, matured DCs matured
with cytokine cocktail (TNF-a, interleukin-1b, IL-6 and prostaglandin
E2) were included. Values represent mean fluorescence intensity
(MFI) standard error of the mean from three independent
experiments. *Increased or decreased MFI with respect to control
(DCs matured with cytokine cocktail) is statistically significant
(P < 0·05).
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PGN + TNF-a and PGN + CD40L induced high levels of
IL-10 and low levels of IL-12p70. Only PGN + poly(I:C)
induced high levels of both IL-10 and IL-12p70. The differ-
ences observed in cytokine expression were not due to
apoptosis, as fewer than 10% of cells stained positively for
annexin V after maturation (data not shown). We could also
not detect transforming growth factor-b1 production (data
not shown). Thus, T cell stimulatory capacity of DCs cor-
related with the state of their phenotypic maturation as
reflected by the levels of co-stimulatory and maturation-
associated molecules as well as Th1-biased cytokine
production.
Polarization of T cell by DCs matured with
different stimuli
We evaluated T cell cytokine responses induced by DC matu-
ration conditions. Purified CD4+ T cells were cultured with
various mDCs, and Th1/Th2 polarization was monitored by
measuring cytoplasmic IFN-g or IL-4 production (Fig. 4). In
line with strong IL-12 production, poly(I:C) alone induced
allogeneic CD4+ T cells preferentially to differentiate towards
a Th1 response, and this was enhanced further by a com-
bination with TNF-a or CD40L as judged by elevated
IFN-g-producing cells with minimal expression of IL-4 by
intracellular cytokine staining. However, TNF-a, CD40L or
PGN alone or in combination induced IFN-g-producing T
cells only weakly (data not shown).
The DCs matured with CD40L and poly(I:C) are
capable to migrate
Maturation of DCs consistently up-regulated CCR7, driving
homing to lymphoid organs. However, CCR7 expression
does not always guarantee acquisition of CCL19/CCL21
responsiveness [19]. We assessed CCL19-driven chemotaxis
of mDCs and found that they possessed the capacity to sense
CCL19 gradients (Fig. 5). While iDCs were able to migrate in
response to IL-8, none of the mDCs showed a significant
migration over the level of DCs matured with cytokine
cocktail. When MIP-3b was introduced, most of the mDCs
showed a comparable migratory capacity, which was
approximately 40% of the capacity of the DCs matured by
cytokine cocktail. DCs matured with CD40L + poly(I:C),
however, exerted a comparable level of migratory activity to
that of cytokine cocktail.
Discussion
The DCs have been used extensively in immunotherapy for
their properties of initiator and modulator of immune
responses, but there are some issues to be addressed for
the clinical application of DCs. First, a large number of
DCs must be generated under sterile cGMP conditions
without using xenogeneic materials such as FBS. Secondly, a
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Fig. 3. Allogeneic T cell proliferation and cytokine secretion by
dendritic cells (DCs) matured with different combinations of
maturation stimuli. (a) Capacity of mature DCs (mDCs) generated
with different combinations of maturation stimuli to induce
allogeneic T cell proliferation. Immature DCs were stimulated with
the indicated maturation stimuli for 48 h, and the mDCs were used to
stimulate proliferation of allogeneic peripheral blood mononuclear
cells (2 ¥ 105 cells/well) at different stimulator : responder ratios. Data
from the stimulator : responder ratio at 1:10 are presented as mean
counts of incorporated [3H]-thymidine. Results shown represent the
mean standard error of the mean (s.e.m.) of four independent
experiments. *Increased or decreased cell proliferation with respect
to control (DCs matured with cytokine cocktail) is statistically
significant (P < 0·05). (b) IL-10 and (c) IL-12p70 were measured in
culture supernatants 48 h later. Results are expressed as mean s.e.m.
of six independent experiments. *Increased cytokine production with
respect to control (DCs matured with cytokine cocktail) is statistically
significant (P < 0·05).
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well-defined protocol should be prepared to generate DCs of
stable phenotype and complete maturation.
The aim of this study was to define effective combinations
of stimulators for generating functionally mDCs from elu-
triated monocytes. The maturation status of DCs is impor-
tant for adequate T cell recruitment, activation, expansion
and differentiation. Maturation of elutriated monocyte-
derived DCs with a conventional cytokine cocktail resulted
in phenotypically mature but functionally inefficient DCs
when X-VIVO 15 was employed. Therefore, we compared
mDCs across categories of maturation stimuli with regard to
phenotype, cytokine production, allogeneic T cell stimula-
tion of DCs, migratory capacity and Th1/Th2 polarization.
These stimuli include PGN, poly(I:C), CD40L and TNF-a
alone or in pairwise combinations.
The PGN has been shown to signal via TLR-2 and the
intracellular pattern recognition receptor Nod2 [20,21].
While the ability of PGN to activate TLR-2 has been ques-
tioned recently, a recent study by Dziarski and Gupta [22]
revealed that S. aureus PGN is indeed a TLR-2 activator.
TLR-3 and melanoma differentiation-associated protein-5
has been implicated in the recognition of poly(I:C) and
dsRNA recognition pattern receptors [23,24]. Some of the
parameters of DC maturation, such as up-regulation of major
histocompatibility complex (MHC) and co-stimulatory mol-
ecules, can be triggered by any of the stimuli mentioned.
IL-12p70 production, however, is induced only by certain
microbial stimuli, such as ligands of TLR-3 and TLR-4, but
not by TNF-a or TLR-2 ligands [21]. The mechanism by
which different maturation signals co-operate in the DC
maturation and function is not yet defined. It has been
reported that TLR synergy leads to sustained c-jun phospho-
rylation and enhances the expression of sets of cytokine genes
including IL-12p70 [25], Th1 responses [26] and CTL
responses in vivo [27].
While mDCs stimulated with the aforementioned stimu-
lators showed typical DC morphology and expressed high
levels of HLA class II, there were some differences in patterns
of phenotypes and cytokine production, implying the
Fig. 4. Intracellular cytokine expression of
dendritic cell (DC)-activated T cells. Immature
DCs, DCs matured with either cytokine
cocktail, polyinosinic : polycytidylic acid
[poly(I:C)] (20 mg/ml) alone or a combination
of poly(I:C) (20 mg/ml) with tumour necrosis
factor-a (10 ng/ml), peptidoglycan (10 mg/ml)
and CD40L (1 mg/ml) were co-cultured with
allogeneic CD4+ T cells. After 7 days of
co-culture, T cells were restimulated with
phorbol 12-myristate 13-acetate and ionomycin
for 8 h. Brefeldin A was added to the culture
during the last 6 h before staining to prevent
cytokine release. Quadrants were set according
to the fluorescence intensities of isotype-
matched control antibodies with irrelevant
specificity. Results from one representative of
three independent experiments are shown.
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Fig. 5. Chemotactic response of dendritic cells (DCs) in response to
major inflammatory protein (MIP)-3b and interleukin (IL)-8. DCs
(1 ¥ 105) were seeded in the upper compartment of Transwell plates
and incubated for 2 h at 37°C in the presence or absence of MIP-3b
(10 ng/ml) or IL-8 (50 ng/ml) added to the lower compartment. DC
counts in the lower chamber wells were measured by flow cytometry.
Chemotaxis in the absence of any chemokines (medium) was the
negative control. Results from one representative of three independent
experiments are shown.
Poly(I:C) plus CD40L on functionally matured DC
371© 2008 British Society for Immunology, Clinical and Experimental Immunology, 154: 365–374
existence of qualitative differences. Poly(I:C) was capable of
inducing DC maturation as measured by the up-regulation
of cell surface markers such as CD86, CD80, CCR7 and
HLA-DR as well as allogeneic T cell stimulation. Combina-
tions with other cytokines, however, failed to augment these
maturation markers.
CD83 is a hallmark of mDCs which also express high
levels of MHC, co-stimulatory, adhesion and activation mol-
ecules [28,29]. Although the function of the CD83 on DCs
remains unclear, studies have indicated its role in the modu-
lation of antigen presentation and T cell activation [30,31].
While previous studies have suggested that expression of
CD83 [32] or CD1a [33] correlated with IL-12 expression
and the functional outcome of resulting DCs, this was not
reflected in our results. Only a fraction of cells expressed
CD83 on mDCs cultured with various combinations of
maturation factors in X-VIVO 15 supplemented with human
AB plasma, suggesting that the maturation factors may
provide insufficient signals for DC maturation. This,
however, is not a new finding, as Napoletano et al. [34]
showed that induction of CD83 was minimal in the serum-
free condition. In our setting, the intensity of CD83 was
enhanced when cells were cultured with human plasma-
supplemented X-VIVO 15, implying that plasma compo-
nents contribute to the expression of CD83. The cause of
discrepancy between our data and the previous reports is not
clear. It could be due to the type of cells (elutriated mono-
cytes versus enriched or purified peripheral blood mono-
cytes), cellular manipulation procedures (elutriation versus
magnetic affinity cell sorting purification) or culture media
and/or instrument setting of flow cytometry in the
experiments. Another variation that can give rise to the dif-
ference may come from the source and/or concentration of
serum employed.
In this study the cytokine cocktail induced the highest
levels of CD83, but little IL-12p70 could be detected in
culture supernatant. This is due most probably to suppres-
sion of IL-12 production by PGE2 [35,36], and the extensive
implementation of this maturation protocol in clinical trials
might explain the limited success of DC vaccination therapy
to date. The production of high levels of IL-12p70 was
attained only in the presence of poly(I:C). IL-12 derived from
DCs plays a central role in the development of IFN-g-
producing Th1 cells [37,38] and this was confirmed by cyto-
plasmic staining of IFN-g in DC-activated T cells. PGN alone
induced strong IL-10 production and this was enhanced
further by combinations with most other stimuli. In general,
signals that induce high IL-12 secretion such as poly(I:C)
[39] promoted Th1 responses and stimuli that enhanced
IL-10 production with or without inducing secretion of
IL-12 (i.e. PGN) elicited less allostimulatory activity and Th1
responses in our system. Although DCs matured with either
TNF-a + poly(I:C) or PGN + poly(I:C) displayed enhanced
IL-12 secretion and some of the maturation markers of DCs,
they were not comparable to that of DCs matured with
CD40L + poly(I:C) in an allostimulatory capacity. While
IL-12 production of DC matured with poly(I:C) or
poly(I:C) + PGN was more efficient than DCs matured with
cytokine cocktails, the T cell stimulatory capacity of DC was
comparable only to conventional DCs, implying that this
parameter is not sufficient for DC capacity. This is due most
probably to weak induction of MHC and co-stimulatory
molecules (such as CD80, CD86) by these stimuli, thus lim-
iting the allostimulatory capacity of mDCs.
One of the major problems in the use of ex vivo-
generated DCs for cancer immunotherapy is their poor
ability to home into draining lymph nodes. This could be
explained by poor expression of chemokine receptor CCR7,
which guides DCs to secondary lymphoid organs, the
sites of initiation of T cell responses in vivo [19,40,41]. We
found that DCs matured with CD40L + poly(I:C) express
CCR7 and had high migration in response to MIP-3b, but
not to IL-8, suggesting that these DCs are likely to be
mDCs that have the potential to migrate in vivo. As all
combinations of maturation factors induced weakly the
expression of CCR7 of DCs generated from elutriated
monocytes, the differences observed in the migration assay
stress the importance of assaying the functionality of the
expressed CCR7 in a migration assay in order to assess the
actual migratory capacity of DCs.
CD40L + poly(I:C)-mDCs showed good capacity to
migrate towards CCL19 and in vitro characteristics that are
important for optimized DCs for immunotherapy: both the
capacity to migrate and to produce IL-12p70. Furthermore,
the CD40L + poly(I:C) combination being a useful type 1
immunity-inducing maturation cocktail with better T cell
stimulation capacity, as evidenced by allostimulation, may
yield superior anti-tumour immune responses and a more
effective clinical outcome than DCs generated by cytokine
cocktail. Some of the data presented contradict previous
reports, and these discrepancies (in immunophenotypes and
cytokine production) may reflect the differences of DC pro-
genitors (CD14+ cells versus elutriated monocytes) or culture
media (conventional versus X-VIVO 15). Alternatively, the
differences noted here may be due to different kinetics of
expression. A deeper understanding of the cellular events
triggered by the activation of each single maturation stimu-
lus or combinations of different stimuli is a prerequisite for
the rational design of successful immunotherapy and vacci-
nation strategies.
In conclusion, we have demonstrated that the require-
ments for generating functionally mature mDCs from elu-
triated monocytes. DCs matured with a combination of
poly(I:C) and CD40L are well suited for immunotherapy,
particularly because it has been feasible to perform large-
scale monocyte isolation as well as ex vivo DC generation in
closed systems using only reagents of cGMP grade through-
out the whole procedure. Comparative clinical trials need to
be initiated to determine whether this approach can result
in more potent DC vaccines for the induction of specific T
S. Kim et al.
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cell-mediated anti-tumour responses to overcome the
limited success of DC vaccination to date.
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